PharmiNews

The Directory of Pharma Companies and News

Actelion

Actelion logo
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.
Category: Biotech
Category: Biotech

Actelion News

DateNews
2017-04-27Publication of the definitive notice of the end result of Actelion tender offer
2017-04-24Publication of the provisional notice of the end result of Actelion tender offer
2017-04-10Actelion amends its financial reporting schedule
2017-04-05Actelion's Annual General Meeting of Shareholders 2017
2017-03-31Johnson & Johnson publishes interim result for Actelion tender offer and declares the tender offer successful
2017-03-15Actelion issues invitation to 2017 Annual General Meeting of Shareholders
2017-03-07Actelion is granted marketing authorization by the European Commission for Ledaga (chlormethine gel) for the treatment o...
2017-03-02Actelion obtains "Epoprostenol ACT" label extension for pediatric PAH patients in Japan
2017-02-16Johnson & Johnson publishes prospectus for Actelion tender offer
2017-02-14Actelion announces excellent financial results for 2016
2017-02-10Actelion concludes second line share repurchase program
2017-01-26JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW R&D COMPANY
2017-01-23Actelion announces results of the MAESTRO study with macitentan in patients with pulmonary arterial hypertension due to ...
2016-12-21Actelion and Johnson & Johnson enter into exclusive discussions
2016-12-21Actelion and Johnson & Johnson enter into exclusive discussions
2016-12-16Actelion receives positive CHMP opinion for chlormethine gel (Ledaga) for the treatment of MF-CTCL
2016-12-14Actelion Update on Strategic Transaction Discussions
2016-11-25Actelion statement
2016-11-07Actelion to provide an update on advancements in its cardiovascular pipeline in PAH and beyond
2016-11-07Actelion announces positive results of the MERIT study with macitentan in patients with chronic thromboembolic pulmonary...
2016-11-03Actelion obtains an option to in-license vamorolone from ReveraGen
2016-10-20Excellent operational results - supported by outstanding Uptravi launch - financial guidance upgraded
2016-10-17New scientific publications highlight the unique profile of Actelion's antimalarial compound
2016-10-13Invitation to discuss Actelion's nine months results 2016
2016-09-29Actelion to investigate all-oral combination therapy for patients with relapsing multiple sclerosis
2016-08-22Actelion completes first-line share purchase program
2016-08-16Actelion receives Swissmedic approval for Uptravi (selexipag) for treatment of pulmonary arterial hypertension
2016-07-21Very strong performance in the first half of 2016 ­- enhanced by successful Uptravi US launch
2016-07-14Invitation to discuss Actelion's half year results 2016
2016-07-07Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia
2016-07-06Actelion initiates Phase III study to evaluate macitentan (Opsumit) in children with PAH
2016-06-15Actelion announces commercial availability of Uptravi (selexipag) in Germany
2016-05-17Actelion is granted marketing authorization for Uptravi (selexipag) in pulmonary arterial hypertension by the European C...
2016-04-21Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio
2016-04-14Invitation: Actelion to discuss first quarter 2016 financial results
2016-04-06Actelion issues invitation to 2016 Annual General Meeting of Shareholders
2016-04-01Positive CHMP opinion for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hypertension readopted
2016-03-22Actelion receives approval for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension in Australia and...
2016-02-29Actelion emphasizes commitment to advance research and care in rare diseases
2016-02-09Actelion presents outstanding 2015 results - Company transformation progressing well
2016-02-02Invitation: Actelion to discuss full year 2015 financial results
2016-01-29Actelion receives positive CHMP opinion for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hypert...
2016-01-26Actelion receives Health Canada approval for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hyper...
2016-01-11Actelion to present at upcoming investor conferences - Actelion 2015-2020 - Transformation on the way
2016-01-04Actelion announces US commercial availability of UPTRAVI (selexipag) as of 4 January 2016
2015-12-23The New England Journal of Medicine publishes "Selexipag for the treatment of pulmonary arterial hypertension"
2015-12-22Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension
2015-12-22Actelion receives US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension
2015-10-22Further data on selexipag (Uptravi) to be presented at CHEST 2015 Congress
2015-10-13Actelion to discuss nine month 2015 financial results
2015-09-23Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at European Respiratory Society (ERS) Congr...
2015-09-10ACTELION STATEMENT
2015-09-05Actelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki award by the 14th International Conferences ...
2015-08-27Additional data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at European Society of Cardiology (ESC) ...
2015-07-21Actelion delivers excellent first half 2015 results
2015-07-16Actelion to discuss first half 2015 financial results
2015-06-26Actelion creates Vaxxilon together with the Max Planck Society
2015-06-25New data supporting gradual up-titration of ponesimod to mitigate first-dose cardiodynamic effects to be presented at EA...
2015-05-13Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at American Thoracic Society (ATS) Conferen...
2015-04-21Actelion delivers excellent results in the first quarter 2015
2015-04-16Actelion to discuss its specialty immunology pipeline compounds
2015-04-16Actelion advances clinical development of its specialty immunology pipeline compounds
2015-04-14Actelion to discuss first quarter 2015 financial results
2015-04-10Actelion issues invitation to 2015 Annual General Meeting of Shareholders
2015-03-26Actelion receives marketing approval for Opsumit (macitentan) in pulmonary arterial hypertension in Japan
2015-03-23Actelion announces commencement of share repurchase program
2015-03-15Selexipag (Uptravi) long-term outcome data in pulmonary arterial hypertension presented at American College of Cardiolog...
2015-03-09Actelion to host an investor event at American College of Cardiology (ACC.15)
2015-03-03Actelion's New Drug Application for selexipag (Uptravi) is accepted by the US FDA with a standard review time
2015-03-02Selexipag (Uptravi) data in pulmonary arterial hypertension to be presented at American College of Cardiology (ACC) 2015
2015-02-16Actelion delivers outstanding 2014 results
2015-01-12Actelion to present at the 33rd J.P. Morgan Healthcare Conference - Transforming our PAH portfolio
2014-12-23Actelion submits US FDA New Drug Application for selexipag (Uptravi) in patients with pulmonary arterial hypertension
2014-12-02Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary arterial hypertension
2014-10-21Actelion delivers strong nine months results
2014-07-22Actelion delivers strong half year operational and financial results
2014-06-16Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hyperten...
2014-05-08Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved
2014-05-05Management Change at Actelion - Roland Haefeli to focus on senior advisory role - Andrew Weiss new Head of Investor Rela...
2014-04-17Actelion announces first quarter 2014 financial results
2014-04-11Actelion issues invitation to 2014 Annual General Meeting of Shareholders
2014-03-17Actelion provides an update on the bosentan study - COMPASS 2
2014-03-13Actelion provides update on Asahi litigation
2014-02-27Actelion's novel antibiotic cadazolid receives US FDA Qualified Infectious Disease Product designation for the treatment...
2014-02-14Opsumit approved by SwissMedic for pulmonary arterial hypertension
2014-02-11Actelion again delivers strong performance in 2013 - Opsumit approved and launched
2014-02-07Actelion receives Therapeutic Goods Administration (TGA) approval in Australia for Opsumit (macitentan) in Pulmonary Art...
2014-01-31Actelion launches Opsumit in Germany
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.